Ionis Pharmaceuticals Price Target Cut to $45.00/Share From $47.00 by JP Morgan

Dow JonesMar 24 08:57 ET

Ionis Pharmaceuticals Is Maintained at Neutral by JP Morgan

Dow JonesMar 24 08:57 ET

Ionis Pharmaceuticals Analyst Ratings

BenzingaMar 24 08:48 ET

J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $45

Moomoo NewsMar 24 06:31 ET

Ionis Pharmaceuticals: Strategic Partnerships and Financial Flexibility Drive Buy Rating

TipRanksMar 17 02:18 ET

Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Raises Target Price to $78

Moomoo NewsMar 13 01:31 ET

William Blair Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating

Moomoo NewsMar 12 10:32 ET

Ionis Pharmaceuticals (IONS) Receives a Buy From William Blair

TipRanksMar 12 09:50 ET

J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $47

Moomoo NewsMar 11 12:31 ET

Ionis Pharmaceuticals Analyst Ratings

BenzingaMar 11 10:56 ET

JP Morgan Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $47

BenzingaMar 11 10:56 ET

Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $38

Moomoo NewsFeb 24 21:32 ET

Stifel Nicolaus Remains a Hold on Ionis Pharmaceuticals (IONS)

TipRanksFeb 24 21:15 ET

Bernstein Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $43

Moomoo NewsFeb 21 10:33 ET

Ionis Pharmaceuticals Is Maintained at Market Perform by BMO Capital

Dow JonesFeb 20 09:32 ET

BMO Capital Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $45

Moomoo NewsFeb 20 08:31 ET

RBC Capital Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $70

Moomoo NewsFeb 20 08:31 ET

Citi Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $64

Moomoo NewsFeb 20 08:31 ET

A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $38 to $70

Moomoo NewsFeb 20 08:01 ET

Ionis Pharmaceuticals: Balancing Strong R&D Revenues With Market Challenges – Hold Rating Justified

TipRanksFeb 20 06:49 ET